NEW YORK, Nov. 17-- The new dual-label Plan B(R) (levonorgestrel) emergency contraceptive arrives in pharmacies this week. To help patients, pharmacists, and healthcare providers understand how this unprecedented product status - Rx and Over-the-Counter (OTC) - will work, Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc., will launch the CARE (Convenient Access Responsible Education) Program, a comprehensive education program for healthcare professionals and consumers.
Approved on August 24, 2006, the new dual-label Plan B(R) is an OTC product for consumers 18 years of age and older and prescription only for women 17 and younger. It is marketed as a single package, which allows for a prescription label to be adhered to the package when dispensed to women age 17 and younger.
"We are pleased with the FDA's historic decision, which gives women more timely access to Plan B(R) emergency contraception," said Amy Niemann, Vice President of Marketing-Proprietary Products at Duramed Pharmaceuticals, Inc. "We are committed to educating consumers on the facts about Plan B(R), as well as how they can purchase the product depending on their age."
Plan B works in the same way a regular daily birth control pill works.
It consists of two tablets of 0.75 mg levonorgestrel (synthetic estrogens), that prevent ovulation or fertilization; it may also inhibit implantation. Once implantation occurs, Plan B(R) is not effective.
BRL ended today's trading largely unchange at $49.52
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment